By the second day of subscription, the IPO had already received a massive 50.63 times subscription, with bids for 26,58,10,750 shares against the 52,50,000 shares on offer.
The China-based cancer drug developer’s offering will fund testing of medicines for several blood malignancies — one of which is part of an alliance with Takeda.